Although considered as a promising therapy since the discovery of the CFTR gene over thirty years ago, CF gene therapy development has proven quite challenging since vectors must have sufficient carrying capacity, express a capsid with tropism for the human airway and be of low immunogenicity. The gene discussed is CFTR; the disease is cystic fibrosis.